U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916130) titled 'A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A' on March 25.
Brief Summary: Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
Study Start Date: April 21
Study Type: INTERVENTIONAL
Condition:
Gastroesophageal Reflux Disease (GERD)
Intervention:
DRUG: AD-120A
Administered before the breakfast during 7 days, Oral, Tablet
DRUG: AD-120
Administered before the breakfast during 7 days, Oral, Tablet
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Addpharma Inc.
Published by HT Digital Content Services with ...